Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

KRROBullishCorporate Developmentsnews

High materiality7/10

Korro Bio Doses First Cohort in ANCHOR KRRO-121 Trial; UCD Dosing on Track for 2027

Oct 5, 2026, 4:13 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive milestone (first cohort dosed) may attract speculative interest; near-term catalysts are 1H2027 dosing and 2H2027 interim readout. Biotech Phase 1/2 progress often yields short-term volatility but requires data to substantiate any longer-term upside.

AI summary

What happened, with direct paths to the underlying reporting

Korro Bio announced the first cohort dosing in its ANCHOR Phase 1/2 KRRO-121 program for hyperammonemia in UCDs and HE. The study starts with healthy volunteers, with UCD dosing expected in 1H 2027 and an interim readout in 2H 2027, highlighting a potential path to infrequent, targeted ammonia control through its OPERA platform.

First KRRO-121 cohort dosed in ANCHOR Phase 1/2; healthy volunteers enrolled.
Single 2 mg/kg dose administered; Part 1 SAD up to 30 volunteers.
UCD patient dosing anticipated in 1H 2027; interim readout in 2H 2027.
KRRO-121 is GalNAc-conjugated REO; aims for pan-UCD/HE ammonia control.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.